Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech Inc. (IOBT) is a clinical-stage biopharmaceutical leader developing T-win platform-based cancer immunotherapies. This dedicated news hub provides investors and researchers with verified updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Access real-time announcements about IO Biotech's innovative pipeline targeting immune inhibitory pathways, including IDO and PD-L1-focused therapies. Our curated collection features earnings reports, research publications, and corporate developments directly from company filings and authorized sources.
Key updates include phase trial results, FDA communications, intellectual property advancements, and executive team announcements. Bookmark this page for streamlined tracking of IO Biotech's progress in advancing novel cancer treatments through methodical clinical evaluation.
IO Biotech (Nasdaq: IOBT) announced that its late-breaking abstract has been selected for oral presentation at the 2025 ESMO Congress in Berlin. The presentation will showcase results from their Phase 3 trial evaluating IO102-IO103 cancer vaccine plus pembrolizumab versus pembrolizumab monotherapy in first-line advanced melanoma.
Additionally, the company will present a poster featuring final data from their Phase 2 basket trial, including efficacy, safety, and survival data for first-line treatment in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of head and neck (SCCHN). The presentations are scheduled for October 19-20, 2025, with Prof. Jessica Hassel delivering the oral presentation and Dr. Jonathan W. Riess presenting the poster.
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory cancer vaccines, has announced its participation in two upcoming investor conferences in New York.
The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45 am ET, featuring a fireside chat with CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad. Additionally, CEO Mai-Britt Zocca will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 8:00 am ET.
Webcasts of both presentations will be available in the Investors section of IO Biotech's website for 90 days following the events.
IO Biotech (Nasdaq: IOBT) reported Q2 2025 financial results and key developments for its cancer vaccine pipeline. The company's Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment showed clinical improvement in progression-free survival, though narrowly missing statistical significance. The study involved 407 patients with unresectable or metastatic melanoma.
Financial highlights include a net loss of $26.2 million in Q2 2025, with cash and equivalents of $28.1 million as of June 30, 2025. The company secured additional funding through a €12.5 million second tranche from the European Investment Bank loan facility in July 2025, extending operations into Q1 2026.
IO Biotech plans to meet with the FDA this fall to discuss potential Biologics License Application submission for advanced melanoma treatment. Initial data from two Phase 2 trials is expected in H2 2025.
IO Biotech (NASDAQ: IOBT) announced topline results from its pivotal Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment. While the combination showed clinical improvement in progression-free survival (19.4 months vs. 11.0 months), it narrowly missed statistical significance with HR=0.77 (p=0.056).
Notable findings include a profound effect in PD-L1 negative patients (16.6 vs. 3.0 months, HR: 0.54, p=0.006) and improved results in patients without prior anti-PD-1 treatment (24.8 vs. 11.0 months, HR: 0.74, p=0.037). The combination demonstrated a positive safety profile with no new safety signals. A trend toward improved overall survival was observed (HR=0.79), though data is not yet mature.
IO Biotech plans to meet with the FDA this fall to discuss potential regulatory submission.
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for August 11, 2025, at 8:30 AM ET to reveal topline results from its pivotal Phase 3 trial (IOB-013/KN-D18). The trial evaluates Cylembio, an investigational immune-modulatory cancer vaccine, in combination with KEYTRUDA® versus KEYTRUDA® alone for first-line treatment of advanced melanoma.
The study focuses on patients with unresectable or metastatic melanoma, with management hosting a live discussion of the results. A replay will be available on the company's website after the event.
IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory therapeutic cancer vaccines, has announced its participation in two upcoming investor conferences. The company's leadership team, including CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Summit on May 27, 2025. Additionally, Dr. Zocca will present at the Jefferies Global Healthcare Conference on June 4, 2025, where the team will also conduct one-on-one investor meetings.
IO Biotech (Nasdaq: IOBT) showcased its scientific leadership at the 2025 AACR Annual Meeting through an educational session on cancer vaccines. The company's scientific co-founder, Dr. Mads Hald Andersen, chaired and presented at the session, focusing on immune-modulatory vaccines (IMVs).
Dr. Andersen's presentation highlighted the dual mechanism of action of IO102-IO103, IO Biotech's most advanced therapeutic cancer vaccine. The vaccine targets both tumor cells and host immune suppressive cells by activating T cells against IDO+ and PDL1+ cells. Recent data suggests it can reprogram the tumor microenvironment (TME) through inflammatory cytokine induction and macrophage phenotypic changes, promoting a more immune-permissive environment.
IO Biotech (IOBT) presented new preclinical data for two cancer vaccine candidates at the AACR Annual Meeting 2025 in Chicago. The company showcased findings for:
1. IO102-IO103: Their lead therapeutic vaccine targeting IDO1 and PD-L1 demonstrated strong T-cell responses and unique tumor microenvironment modulation in mouse models, with effects distinct from conventional PD-1/PD-L1 inhibitors.
2. IO170: Their TGF-β-directed vaccine showed significant tumor growth inhibition in breast and prostate cancer models, increasing CD8+ T-cell density and reducing suppressive cells like M2 macrophages.
Both vaccines, developed using IO Biotech's T-win® platform, showed promising results in reshaping the tumor microenvironment to enhance anti-tumor immunity.
IO Biotech (IOBT) announced the acceptance of two abstracts for presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase new non-clinical data for their cancer vaccine candidates:
1. Data demonstrating how IO102-IO103, their lead candidate currently in Phase 3 trials for advanced melanoma, controls tumor growth through target-specific T-cell activation.
2. Preclinical data for IO170, their pipeline candidate targeting TGF-beta, showing promising antitumor activity.
Additionally, Dr. Mads Hald Andersen, the company's scientific co-founder, will chair and speak at an educational session on cancer vaccines, exploring the latest advances in cancer vaccine research.
FAQ
What is the current stock price of Io Biotech (IOBT)?
What is the market cap of Io Biotech (IOBT)?
